"Our top executives from the Paris headquarters have committed significant investments in India. It is difficult to quantify how much investment will come here in the coming years but it will be need based," said Shailesh Ayyangar, managing director, Aventis Pharma, on the sidelines of the launch of SoloStar, its disposable pen for the administration of insulin.
At present, sanofi-aventis has two large manufacturing facilities, one at Ankleswar for active pharmaceutical ingredients (API) and the other in Goa for making tablets.
Manufacture of vaccines and other products from India will be another area of focus for the